Hsbc Holdings PLC Genmab A/S Transaction History

Hsbc Holdings PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$30.92 - $44.4 $167,400 - $240,381	-5,414 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$33.66 - $40.76 $36,958 - $44,754	-1,098 Reduced 16.86%	5,414 $220,000
Q3 2020 Nov 12, 2020	SELL	$33.07 - $38.68 $78,375 - $91,671	-2,370 Reduced 26.68%	6,512 $238,000
Q2 2020 Aug 14, 2020	SELL	$20.05 - $33.89 $79,698 - $134,712	-3,975 Reduced 30.92%	8,882 $301,000
Q1 2020 May 15, 2020	BUY	$17.15 - $25.22 $720 - $1,059	42 Added 0.33%	12,857 $272,000
Q4 2019 Feb 14, 2020	SELL	$18.88 - $24.14 $24,544 - $31,382	-1,300 Reduced 9.21%	12,815 $286,000
Q3 2019 Nov 14, 2019	BUY	$18.0 - $21.38 $254,070 - $301,778	14,115 New	14,115 $286,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.